FU
FUM.LSE Futura Medical
- Market cap
- GBX 2.74M
- P/E
- -
- P/B
- 1.29x
- ROE
- -235.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is FUM.LSE undervalued?
Graham numberThe Graham number of Futura Medical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Futura Medical fundamental analysis
No fundamental analysis for Futura Medical yet.
Futura Medical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Futura Medical
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical treatment for erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United King…
Full company profileFutura Medical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Futura Medical annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 170K | 363K | 0.00 | 31.8K | 0.00 | 0.00 | 0.00 | 3.10M | 13.9M | 1.70M | 6.49M |
| Gross Profit | 170K | 363K | -19.9K | 31.8K | -25.0K | -19.8K | -24.7K | 1.77M | 9.57M | 1.24M | 6.26M |
| Operating Income | -4.55M | -4.86M | -7.27M | -11.2M | -2.93M | -5.87M | -6.87M | -6.96M | 1.18M | -5.66M | -5.19M |
| EBITDA | -4.55M | -4.84M | -7.22M | -11.1M | -2.90M | -5.85M | -6.85M | -6.83M | 1.41M | -5.54M | -4.96M |
| Net Income | -3.70M | -3.90M | -5.88M | -8.92M | -2.41M | -4.96M | -5.85M | -6.51M | 1.29M | -9.07M | -4.72M |
| EPS | -0.04 | -0.03 | -0.04 | -0.04 | -0.01 | -0.02 | -0.02 | -0.02 | 0.00 | -0.03 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 13.4M | 9.60M | 10.9M | 4.90M | 1.62M | 11.8M | 6.47M | 11.8M | 13.6M | 5.22M | 4.15M |
| Total Liabilities | 855K | 499K | 2.03M | 4.85M | 767K | 2.08M | 1.75M | 6.34M | 4.63M | 2.41M | 2.15M |
| Shareholders' Equity | 12.6M | 9.11M | 8.85M | 53.7K | 854K | 9.72M | 4.72M | 5.48M | 8.96M | 2.81M | 2.01M |
| Cash & Short-term Investments | 12.4M | 8.36M | 9.16M | 2.51M | 1.02M | 10.4M | 4.03M | 7.71M | 6.60M | 3.40M | 1.24M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.30M | -4.17M | -4.71M | -6.66M | -4.54M | -3.87M | -5.78M | 570K | 438K | -5.62M | -8.63M |
| Capital Expenditure | 7.48K | 55.6K | 4.51K | 32.7K | 8.37K | 420K | 741K | 1.51M | 1.73M | 3.00 | 0.00 |
| Free Cash Flow | -3.31M | -4.23M | -4.71M | -6.69M | -4.55M | -4.29M | -6.52M | -936K | -1.29M | -5.58M | -8.63M |
| Ratios | |||||||||||
| ROE | -29.4% | -42.8% | -66.4% | -16,624.3% | -282.2% | -51.0% | -123.9% | -118.9% | 14.4% | -323.4% | -235.6% |
| ROA | -27.5% | -40.6% | -54.1% | -182.0% | -148.7% | -42.0% | -90.3% | -55.1% | 9.5% | -173.8% | -113.8% |
| Net Profit Margin | -2,170.2% | -1,075.3% | - | -28,067.5% | - | - | - | -210.0% | 9.3% | -534.6% | -72.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Futura Medical dividends
Futura Medical has not paid dividends in the last 9 fiscal years.
Last stock split: 703:699 on Oct 22, 2018.
Who owns Futura Medical
- Insiders 44.26%
- Institutions 11.38%
- Public & others 44.37%
- Shares outstanding 1.48B
- Free float 371M
Futura Medical company profile
- Company name
- Futura Medical
- Ticker
- FUM.LSE
- ISIN
- GB0033278473
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 13
- Fiscal year end
- December
- Address
- Surrey Technology Centre, Guildford, United Kingdom, GU2 7YG
- Phone
- 44 14 8368 5670
- Website
- futuramedical.com
About Futura Medical
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical treatment for erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
Futura Medical management
5- Mr. Alexander James Hanbury DugganCEO & Executive Director · born 1970
- Ms. Angela HildrethCOO, Finance Director, Company Secretary & Executive Director · born 1980
- Mr. Kenneth William JamesHead of R&D & Executive Director · born 1952
- Dr. William Duncan Potter BSc (Hons), MSc, Ph.D.Chief Scientific Officer & Adviser to the Board · born 1948
- Mr. Kevin LangridgeHead of Quality